metabolite. At the very least, Applicants submit that the claims of Groups I and II be considered in this application, since the claims of Group II (i.e., claims 16-45) are directed to pharmaceutical compositions and dosage forms that can be used in the methods of Group I.

On page 4 of the Office Action, a selection of species is required. Applicants select neuroleptic disorders, which are disclosed at, for example, page 6, lines 9-10 of the Specification.

Respectfully submitted,

Date: August 28, 2001

Dackson (Davido

(Reg. No.)

PENNIE & EDMONDS LLP

1667 K Street, N.W. Washington, D.C. 20006

(202) 496-4400

For: Anthony M. Insogna

(Reg. No. 35,203)

PENNIE & EDMONDS LLP 1155 Avenue of the Americas New York, New York 10036-2711

(212) 790-9090

Enclosure